cyrilzakka/clinical-trials huggingface dataset:
Effects of Uremia on Brachial Plexus Electrophysiology and Brachial Plexus Block

As a late stage of renal failure, uremia not only leads to severe impairment of renal function in patients, but also often leads to a variety of complications, among which multiple peripheral neuropathy is particularly common. This lesion is mainly caused by the combination of multiple mechanisms, such as the accumulation of uremic toxins, electrolyte disorder, nutrient deficiency and factors related to hemodialysis. Therefore, it is important clinical significance to deeply explore the effects of uremia on electrophysiological properties and nerve block of brachial plexus.

At present, there are relatively few studies on the effects of uremia on the brachial plexus, especially the prospective parallel cohort studies on its electrophysiological properties and nerve block. As a new anesthetic technique, ultrasound-guided axillary brachial plexus block has the advantages of precise positioning, scientific administration, reducing complications and improved safety, but the application effect and safety in uremic patients still need to be further verified.


Eligibility Criteria:
Inclusion Criteria:

* Uremia group \[group U\]

  1. Patients aged 18 years and older
  2. ASA classification I-IV
  3. BMI 18.5-29.9
  4. Patients with uremia planning to undergo forearm or hand surgery
  5. Diagnostic criteria: Patients must meet the internationally recognized diagnostic criteria for uremia and require hemodialysis
  6. Informed consent: Patients or their legal representatives must sign an informed consent form, agreeing to participate in this study and undergo related examinations and treatments
* Non-uremia group \[Group N\]

  1. Patients aged 18 years and older
  2. ASA classification I-IV
  3. BMI 18.5-29.9
  4. Patients planning to undergo forearm or hand surgery
  5. In addition to possibly having diabetes, patients should not have any other diseases that could cause peripheral neuropathy
  6. The patient or their legal representative must sign an informed consent form, agreeing to participate in this study and receive the relevant examinations and treatments

Exclusion Criteria:

* Individuals allergic to study medications (such as ropivacaine)
* Those with contraindications to local anesthesia or nerve blockades, such as coagulation disorders, infections, etc.
* Those with severe cardiovascular or respiratory diseases
* Those unable to comply with study requirements, such as cognitive impairment, mental disorders, etc.
* Pregnant women
Multi-center Study on Reducing Postoperative Pulmonary Complications in Elderly Patients

The purpose of this study is to carry out demonstrative comprehensive intervention for elderly patients in several hospitals to observe whether it can reduce the incidence and mortality of perioperative pulmonary complications in elderly patients and improve their perioperative prognosis.

This study investigated the incidence of postoperative pulmonary complications in various hospitals, and carried out demonstrative comprehensive intervention for elderly patients in several hospitals according to the comprehensive intervention system program of perioperative pulmonary complications, to observe whether the perioperative prognosis can be improved and the quality of life can be improved, thus verifying and optimizing the current evaluation system and intervention system, and providing evidence support for further extensive application.

Eligibility Criteria:
Inclusion Criteria:

1. age 65 years or older
2. receiving invasive ventilation during general anesthesia for surgery

Exclusion Criteria:

1. preoperative mechanical ventilation
2. procedures related to a previous surgical complication
3. a second operation after surgery
4. organ transplantation
5. discharged within 24 hours after surgery
Comparison Study of BNP and Thoracic Impedance Measurements on Arrhythmias

It is hypothesized that elevated BNP level correlate with an elevated thoracic impedance/fluid index as measured separately by CRT-D devices and external impedance cardiography. Ultimately, it is also hypothesized that both BNP and thoracic impedance/fluid index measurements are predictive of atrial and ventricular arrhythmias.

The primary aim of this study:

1. To assess the correlation between elevated brain natriuretic peptide levels and elevated thoracic impedance/body fluid index as measured by selective biventricular resynchronization devices and an external impedance cardiography device.
2. Correlate impedance measurements and brain natriuretic levels with occurrence of atrial and ventricular arrhythmias as assessed by interrogation of biventricular devices.

Eligibility Criteria:
Inclusion Criteria:

* Male or female between 18 to 85 years of age.
* All patients with biventricular implantable cardio-defibrillators(manufacturer: Medtronic/ model: InSync 7299/7297 or newer).
* LVEF \<35%
* NYHA III/IV
* QRS \>120 msec
* Pt willing and able to sign informed consent.
* Conventional heart failure therapy
* Clinically stable for six months.

Exclusion Criteria:

* age less than 18 years of age
* age greater than 85 years of age
* Creatinine \> 2.5 mg/dl.
* End stage liver disease complicated by ascites as determined by electronic medical record review.
* women who are pregnant, lactating, or plan to become pregnant during the course of the study.
* Patients who are heart transplant candidates with expected transplantation within the next six months.
* Life expectancy due to non-cardiac cause less than one year.
* Anticipated problem with compliance.
* Critical valvular stenoses/insufficiencies.
* Morbidly obese patients(\>300 lbs.)
* In patients whom impedance cardiography was not able to be performed because of inability to place sensors.
* Planned or known need for revascularization procedures within three months.
Effect of a Hydrogen-Peroxide and Hyaluronic-Acid Mouthwash (BMG0703) in the Treatment of Periodontitis

Assessment of the efficacy of BMG0703 in the treatment of periodontitis and control of supragingival plaque, compared to Chlorhexidine and a placebo product

The enrolled subjects will be examined and treated by specialized medical personnel.

Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.

Next, subjects will be divided into three groups: after the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with the test product, active comparator or placebo, with the aid of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.

One bottle of the product (test, comparative or placebo) will then be given to the patient who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.

The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth).

Patients with allergic reactions or hypersensitivity due to the use of the products will be advised to discontinue the use of the products and seek medical advice.

Eligibility Criteria:
Inclusion Criteria:

* Presence of periodontitis with pockets between 3 and 7 mm
* Acceptance of informed consent

Exclusion Criteria:

* subjects suffering from HIV
* subjects suffering from hepatitis
* serious systemic diseases preventing the use of specific dental therapies
* acute and/or chronic infectious pathologies
* inability to provide consent
* use of topical or systemic drugs
* inability to follow post-intervention hygiene instructions
* smokers
Safety Study to Evaluate BMS-830216 in Healthy Subjects

The purpose of this study is to evaluate the safety profile, tolerability, and pharmacokinetics of single oral doses from 10 mg up to 1200 mg of BMS-830216 (pro-drug of BMS-819881) in healthy subjects


Eligibility Criteria:
Inclusion Criteria:

* Healthy male and female subjects as determined by medical history, physical examination, 12-lead electrocardiogram (ECG), and clinical laboratory evaluations will be eligible to participate in the study
* Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and men between ages of 18 to 45

Exclusion Criteria:

* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations
Quality of Life in Juvenile Patients With Uveitis

Data about psychodynamics in uveitis patients are scare. A negative impact of disease is described not only in adult patients with active, but also with quiescent disease. During adolescence even less is known about psychodynamics although this is an especially sensible and challenging stage of life. Given the assumption that juvenile patients with quiescent disease still could suffer from emotional distress, this would require special attention.

In this study the investigators evaluate the impact of juvenile uveitis on HRQoL and attempted to identify clinical and demographic factors contributing to an impaired health status. The investigators limit the study to patients with quiescent uveitis and good visual function in at least one eye to exclude additional negative stressors. As there are no validated uveitis-specific psychometric questionnaires evaluating QoL available yet, the investigators use age-appropriate generic instruments. This should allow obtaining an overview about the adolescents' general Health-related Quality of Life (HRQoL) and whether psychological interventions should be offered to this sensitive patient group.


Eligibility Criteria:
Inclusion Criteria:

* Patients with uveitis
* aged 11-18 years
* willing to participate
* parent or legal guardian agrees with participation of adolescent

Exclusion Criteria:

* not willing to participate
* parent or legal guardian does not agree with participation of adolescent
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

The purpose of this study is to assess the efficacy and safety of S1 combination with Anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence after at least one standard chemotherapy.

Although SCLC is very responsive to initial treatment, most patients relapse with relatively resistant disease.These patients have a median survival of only 4 to 5 months when treated with further systemic therapy. Improvements in therapy for relapsed SCLC are much needed.The purpose of this study is to assess the efficacy and safety of S1 combination with Anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence after at least one standard chemotherapy.

Eligibility Criteria:
Inclusion Criteria:

* Histological or cytologically confirmed small cell lung cancer;
* Systemic chemotherapy that has previously received at least one or more lines regimen, followed by disease progression or recurrence;
* Age 18-75 years,ECOG PS:0-2,Life expectancy of more than 3 months
* participants had at least one measurable target lesion by RECIST1.1
* The main organ function meets the following criteria:absolute value of neutrophils ≥ 1.5 × 109 / L, platelets ≥80 × 109 / L, hemoglobin ≥ 80 g / L;total bilirubin ≤ 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal value (if liver metastasis, ≤ upper limit of normal value 5 times), serum creatinine ≤ 1.5 times the upper limit of normal;
* Patients should participate in the study voluntarily and sign informed consent

Exclusion Criteria:

* Patients who have been used anti-angiogenesis inhibitors,such as (such as sunitinib,bevacizumab,endostar et al.
* Subjects with symptomatic brain metastases;
* Patients whose primary lesion with active bleeding within 4 months
* Hypertension, which is uncontrolled by the drug, is defined as: systolic blood pressure ≥ 160 mmHg, or diastolic blood pressure ≥ 100 mmHg
* Patients with active or unable to control serious infections
* Patients who are pregnant or breastfeeding.
Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease

PRIMARY: To compare the frequency of and time to relapse of Cytomegalovirus (CMV) gastrointestinal disease following foscarnet induction therapy only versus induction plus maintenance therapy.

SECONDARY: To determine frequency of and time to recurrence of gastrointestinal symptoms, response rate of pathological lesions, and incidence of nongastrointestinal CMV disease in this patient population.

Patients receive intravenous foscarnet either as induction only for 4 weeks or as induction for 4 weeks followed by maintenance for 22 weeks. All patients are followed for 26 weeks or until relapse.

Eligibility Criteria:
Inclusion Criteria

Patients must have:

* AIDS.
* CMV GI disease.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Non-GI CMV disease.
* Ulcerative colitis, inflammatory bowel disease, or other condition that may interfere with study results.
* Other GI pathogens.

Concurrent Medication:

Excluded:

* Drugs that may interact with foscarnet.
* Systemic acyclovir, ganciclovir, or acyclovir prodrug.
* Drugs known to affect renal function.

Prior Medication:

Excluded:

* Prior foscarnet in extremis.
* Investigational agents other than 3TC or d4T within 7 days prior to study entry.
Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia

OBJECTIVES: I. Compare the efficacy of preventive vs. therapeutic tin mesoporphyrin in direct Coombs' test-positive ABO hemolytic disease of the newborn and glucose-6-phosphate dehydrogenase deficiency in infants living in Greece.

II. Assess the safety of tin mesoporphyrin in high-risk newborns.

PROTOCOL OUTLINE: Patients are stratified by gestational age and sex, and randomly assigned in pairs per stratum.

One group receives a preventive dose of tin mesoporphyrin. Another group receives a therapeutic dose of tin mesoporphyrin according to the plasma bilirubin concentration.

Patients in either group may be treated concurrently with phototherapy or exchange transfusion if clinically indicated.

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Hyperbilirubinemia associated with either of the following: Direct Coombs' test-positive ABO hemolytic disease of the newborn Glucose-6-phosphate dehydrogenase deficiency --Prior/Concurrent Therapy-- No maternal phenobarbital in last month of pregnancy --Patient Characteristics-- Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: No congenital renal abnormality Cardiovascular: No congenital heart abnormality Pulmonary: No asphyxia requiring assisted ventilation at delivery Other: Gestational age more than 210 days Birth weight at least 1500 g No other major congenital abnormality, i.e.: Central nervous system Chromosomal Gastrointestinal No evident or suspected congenital infection, e.g.: Cytomegalovirus Herpes Rubella Syphilis
Arterial Calcifications in Nocturnal Hemodialysis and Renal Transplantation Versus Conventional Dialysis

Objective:

1. To assess whether nocturnal hemodialysis and renal transplantation are associated with less progression of coronary arterial calcification, compared with conventional hemodialysis and peritoneal dialysis;
2. To identify the risk factors for coronary arterial calcification in dialysis and transplant patients, and to assess a possible interaction with treatment modality.

To assess whether nocturnal hemodialysis and renal transplantation are associated with less progression of coronary arterial calcification, compared with conventional hemodialysis and peritoneal dialysis; To identify the risk factors for coronary arterial calcification in dialysis and transplant patients, and to assess a possible interaction with treatment modality.

Eligibility Criteria:
Inclusion Criteria:

* ESRD
* current age \> 18 and \< 75 yr
* ability to understand the study procedures
* willingness to provide written informed consent

Exclusion Criteria:

* life expectancy \< 3 months
* claustrophobia
* allergy to iodinated contrast
* treatment incompliance, i.e. non-adherence to dialysis regimens and drug use
* GFR \< 30 ml/min (according to MDRD formula) in renal transplant patients
* pregnancy
Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients

MTR107 effect on blood pressure throught the dialysis procedure and its ability to prevent Intra dialytic Hypotension

The present clinical trial aims to investigate and provide a more precise characterization of the pharmacokinetic and pharmacodynamic profile of MTR107 in a population of ESRD patients predisposed to developing intradialytic hypotension. The study is also designed as a dose esclating study aiming to assess MTR107 safety.

Eligibility Criteria:
Inclusion Criteria:

1. Age 20-75 years, inclusive.
2. Presence of frequent bouts of hypotension defined as 3 or more intradialytic hypotensive events per month for the last six months prior to baseline, despite standard adjustments in dry weight.
3. ECG performed up to one month before study start.
4. Well-preserved hepatic function (within normal laboratory ranges) at study entry as judged by:

   * Serum Bilirubin (Total Bilirubin (direct and indirect) 0.3-1.0 mg/dL, and Direct Bilirubin 0.1-0.5 mg/dL)
   * Serum Albumin (\>3.6 g/dL),
   * Serum aminotransferases (AST (0-37 U/L) and ALT (0-40 U/L)),
   * GGT (Gamma Glutamine Trans Peptidase)
5. Normal coagulation status at study entry as judged by PT-INR, PTT, fibrinogen and platelet count.
6. Willingness to participate in the study and adhere to the study design.
7. Willingness to sign an informed consent form.

Exclusion Criteria:

1. Uncontrolled hypertension \>140/90 mmHg.
2. Unstable angina.
3. Abnormal ECG which may indicate acute disease
4. Variable weight gains.
5. Mental retardation.
6. Pregnancy.
7. Malignancy or other concomitant serious diseases.
8. Current participation in another clinical trial involving an investigational drug/device, or participation in such a trial within the last 30 days.
Effect of Modified Poco-Poco Exercise to Frailty Stages, Expression of Global DNA Methylation, GDF15 and Lamin A COP

The goal of this clinical trial is to know the effect of multicomponent exercise in frail elderly in community to aging hallmarks. The main question\[s\] it aims to answer are:

1. Do global DNA methylation levels change in elderly people in Bandung after receiving modified poco-poco exercise?
2. Do GDF15 levels change in elderly people in Bandung after they are given modified poco-poco exercise?
3. Do lamin A COP levels change in elderly people in Bandung after they are given modified poco-poco exercise?
4. Does the level of frailty in elderly people in Bandung change after they are given modified poco-poco exercise?

Participants will be asked to do flexibility, balance, aerobic and strengthening exercise included in poco-poco modified exercise three times a week for 12 weeks

The elderly population in West Java Province with the age category of 60-64 years is 1.76 million people. Experts estimate that 25.2% of the Indonesian population experiences frailty. Frailty can lead to a variety of worsening health conditions. The frailty process is thought to stem from the failure of various mechanisms associated with markers of aging. Markers of aging are divided into three categories: primary, antagonistic and integrative. Biomarkers representing these three categories are global DNA methylation, GDF15 and Lamin A COP. Multicomponent exercise is the most effective intervention in elderly with frailty. Elderly people in West Java on average only have an education equivalent to junior high school (SMP), so activities that promote physical activity are better focused on health activities in the community. The poco-poco exercise that is currently commonly practiced almost fulfills the rules of multicomponent exercise for frailty elderly, but poco-poco exercise does not have a muscle strengthening exercise component, so a modified poco-pcoco exercise was created to fulfill this method.

Eligibility Criteria:
Inclusion Criteria:

1. Frailty level is in pre-frailty
2. MoCA INA score above 18
3. Domicile in Bandung City
4. Willing to participate in the study after informed consent

Exclusion Criteria:

1. There is a hearing impairment that may prevent the subject from receiving verbal instructions
2. There is uncorrected visual impairment
3. There are musculoskeletal disorders so that they cannot perform exercise procedures or procedures for measuring research variables
4. Subjects received other rehabilitation programs
5. Post-stroke with average limb muscle strength below three
6. There are diseases that cause impaired cognition such as Alzheimer\&#39;s disease, traumatic head injury, Parkinson\&#39;s disease.
7. There are severe joint diseases such as osteoarthritis and rheumatoid arthritis that may worsen during exercise or may cause difficulty in carrying out the exercise program.
8. Severe cardiovascular disease as assessed by a heart and vascular specialist
9. Unable to attend Exercises regularly
A Study of N-acetylcysteine in Patients With COVID-19 Infection

The study researchers think that a medication called N-acetylcysteine can help fight the COVID-19 virus by boosting a type of cell in your immune system that attacks infections. By helping your immune system fight the virus, the researchers think that the infection will get better, which could allow the patient to be moved out of the critical care unit or go off a ventilator, or prevent them from moving into a critical care unit or going on a ventilator.

The US Food and Drug Administration (FDA) has approved N-acetylcysteine to treat the liver side effects resulting from an overdose of the anti-inflammatory medication Tylenol® (acetaminophen). N-acetylcysteine is also used to loosen the thick mucus in the lungs of people with cystic fibrosis or chronic obstructive pulmonary disease (COPD). This study is the first to test N-acetylcysteine in people with severe COVID-19 infections.


Eligibility Criteria:
Inclusion Criteria:

* Documented COVID-19 infection (either performed on site or documented external report)
* Age ≥ 18

Arm A:

* Admission to an intensive care unit at MSK (M-11) and/or receiving mechanical ventilation
* Absolute lymphocyte count ≤ 1.0/mm3
* As the ALC of patients with lymphoid malignancies is unreliable, they may be enrolled at the discretion of the treating physician after review of their blood work.

Arm B:

* Arm B:Requiring 2L or more of supplemental oxygen by nasal cannula or higher to maintain SpO2 of 95%

Exclusion Criteria:

Arm B:

* requiring mechanical ventilation or admission to an intensive care unit at MSK (M11)